Biological modifiers as cytoreductive therapy before stem cell transplant in previously untreated patients with multiple myeloma

Annals of Oncology

Volumn 16, Issue 2, 2005, Pages 219-221

  Aviles A ^a,b   Nambo, M J ^a   Neri, N ^a   Murillo, E ^a   Castaneda C ^a   Cleto, S ^a   Talavera, A ^a   Gonzalez M ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b NONE   (Mexico)

Author keywords

All trans retinoic acid; Dexamethasone; Interferon; Multiple myeloma

Indexed keywords

ALPHA2A INTERFERON; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; RETINOIC ACID; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; MULTIPLE MYELOMA; MYCOSIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPTICEMIA; SKIN TOXICITY; THROMBOCYTOPENIA; TUMOR GROWTH; VIRUS INFECTION;

EID: 14644440819     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi048     Document Type: Article

References (15)

1. Barlogie B, Schaughnessy J, Tricot G et al. Treatment of multiple myeloma. Blood 2004; 103: 20-36.
2. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
3. Ogata A, Nishimoto N, Shima Y et al. Inhibitory effects of all-trans retinoic acid on the growth of freshly isolated myeloma cells and interference with interleukin-6 signal transduction. Blood 1994; 84: 3046-3056.
4. Palumbo A, Batagglio S, Napoli P et al. Retinoic acid inhibits the growth of human myeloma cells in vitro. Br J Haematol 1995; 89: 555-561.
5. Puthier D, Bataille R, Barrile S et al. Myeloma cell growth arrests apoptosis and interleukin-6 receptor modulation induced by E.B. 1089 a vitamin D3 derivative alone or in combination with dexamethasone. Blood 1996; 88: 4059-4066.
6. Matsui W, Huff CA, Vala M et al. Anti-tumor activity of interferon alpha in multiple myeloma. Role of interleukin-6 and tumor cell differentiation. Br J Haematol 2003; 121: 251-258.
7. Smith JR, Xiet T, Joshi I, Childer RJ. Dexamethasone, plus retinoic acid decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells. Br J Haematol 1998; 102: 1090-1097.
8. Chen YH, Desai P, Shiad RT et al. Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: Synergy through modulation of interleukin-6 autocrine loop at multiple sites. Blood 1996; 87: 314-322.
9. San Miguel JF, Moro M, Bláde J et al. Combination of interferon and dexamethasone in refractory multiple myeloma. Hematol Oncol 1990; 8: 185-189.
10. Musto P, Sajeva MR, San Paolo G et al. All-trans retinoic acid in combination with alpha interferon and dexamethasone for advanced multiple myeloma. Haematologica 1997; 82: 354-356.
11. Juturi J, Bokows RA, Bucock K et al. High-intermittent dose for all-trans retinoic acid in combination with alpha interferon for advanced multiple myeloma. Haematologica 2001; 86: 776-777.
12. Avilés A, Rosas A, Huerta-Guzmán J et al. Dexamethasone, all-trans retinocid acid and interferon alpha 2a in patients with refractory multiple myeloma. Cancer Biother Radiophar 1999; 14: 23-27.
13. The U.K. Myeloma Forum Guidelines Working Group. Diagnosis and management of multiple myeloma. Br J Haematol 2001; 125: 522-540.
14. Bladè J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
15. Zervas K, Dimopoulus MA, Hatzicharissi E et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004; 15: 134-138.